... psoriasis and Crohn's disease; and a diabetes drug similar to Merck's (nyse: MRK - news - people ) blockbuster Januvia. Pain drugs are one focus. ...
... that could treat rheumatoid arthritis and other inflammatory diseases; and a diabetes medicine that uses a mechanism similar to Merck's Januvia. ...
... that could treat rheumatoid arthritis and other inflammatory diseases; and a diabetes medicine that uses a mechanism similar to Merck's Januvia. ...
Now that Galvus and Eucreas are available in Europe, Novartis can now take on Merck & Co’s rival product Januvia (sitagliptin) and analysts believe that ...
JANUVIA is expected to be available to purchase on prescription from March. JANUVIA is the first in a new class of drugs known as dipeptidyl peptidase-4 ...
Globally marketed as Januvia, Merck’s Sitagliptin recorded $668 million in worldwide sales in 2007 and is projected to reach $2 billion by 2011. ...
all 5 news articles
Now that Galvus and Eucreas are available in Europe, Novartis can now take on Merck & Co’s rival product Januvia (sitagliptin) and analysts believe that ...
Our DP-IV patent estate continues to be a very valuable asset to the organization and with Merck reporting a 2007 annualized exit run-rate for Januvia and ...
... drugs like Merck's Januvia and Amylin/Lilly's Byetta are likely to be adopted by international guidelines and recommended treatment algorithms in the ...